Blockchain Registration Transaction Record

Silo Pharma Files Patent for Ibogaine-Based TBI and PTSD Therapies

Silo Pharma files patent for ibogaine-based therapeutics targeting traumatic brain injury and PTSD. Learn about the company's pipeline and strategic initiative in CNS disorders.

This news matters because traumatic brain injury and PTSD affect millions worldwide, yet current treatments are limited. Silo Pharma's exploration of ibogaine, a psychedelic compound, could lead to novel therapies that address the root causes of these conditions, offering new hope for patients. The patent filing signals a strategic shift in the biopharmaceutical industry toward psychedelic-based treatments, potentially opening up a new market for CNS disorders. For investors, the company's unique combination of biotech and cryptocurrency treasury adds a layer of diversification, while the collaboration with academic institutions enhances credibility.